Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended 30 September 2013
Issuance Date: 23 October 2013
GSK reported broadly-based sales growth with Group turnover increasing 1% at constant exchange rates (CER). The quarter was characterized by significant pipeline approvals, continued cost efficiencies, and strategic divestitures. The company reaffirmed its full-year 2013 guidance.
Key Financial Metrics
| Metric | Q3 2013 (£m) | Q3 2013 CER Growth | 9 Months 2013 (£m) | 9 Months 2013 CER Growth |
|---|---|---|---|---|
| Turnover | 6,510 | +1% | 19,599 | -0% |
| Core Operating Profit | 2,059 | +11% | 5,927 | -0% |
| Core Operating Margin | 31.6% | N/A | 30.2% | N/A |
| Core Earnings Per Share (EPS) | 28.9p | +16% | 82.1p | +5% |
| Total Operating Profit | 1,569 | -5% | 4,587 | -14% |
| Total EPS | 20.0p | -12% | 61.4p | -17% |
| Net Cash Inflow from Operations | 2,077 | N/A | 5,035 | N/A |
| Free Cash Flow | 1,511 | N/A | 3,223 | N/A |
| Net Debt | 15,088 | N/A | 15,088 | N/A |
Note: CER growth excludes the impact of exchange rate fluctuations. Total results include non-core items such as restructuring costs, legal charges, and intangible amortization.
Material Changes vs. Prior Period
- Revenue Mix: Pharmaceuticals and Vaccines sales were flat at CER, while Consumer Healthcare grew 4% (CER). Growth in the US (+2%) and Europe (+5%) was offset by a significant decline in EMAP (-9%), driven primarily by a 61% drop in China sales due to an ongoing government investigation.
- Profitability: Core operating profit grew 11% in Q3, driven by cost control, reduced R&D expenditure, and savings from restructuring post-retirement medical obligations (£267m benefit). Total operating profit declined due to non-core charges of £490m in Q3 (compared to £291m in Q3 2012).
- Divestitures: GSK announced agreements to divest Lucozade and Ribena to Suntory for £1.35 billion and Arixtra/Fraxiparine to Aspen for £700 million, totaling over £2 billion in non-core asset sales.
- Product Performance: Oncology sales grew 23% in Q3, led by Votrient (+84%) and Promacta (+43%). Respiratory sales declined 2% due to wholesaler de-stocking in the US and pricing pressures in Europe.
Guidance, Outlook, and Risks
Full Year 2013 Guidance: Reaffirmed. GSK expects core EPS growth of 3-4% (CER) on sales growth of around 1% (CER).
Management Commentary:
- Pipeline: Significant progress with 4 new approvals (Tivicay, FluLaval Q-IV, Tafinlar, Relvar Ellipta) and positive regulatory recommendations for Anoro Ellipta and Relvar Ellipta.
- Shareholder Returns: Declared a Q3 dividend of 19p (+6%). Repurchased £1 billion of shares by end of Q3, targeting £1-2 billion for the full year.
- Cost Efficiency: Continued delivery of operating and financial efficiencies, with R&D expenditure down 10% in Q3.
Risks and Contingencies:
- China Investigation: Ongoing investigation into GSK China's operations has caused a significant sales decline (-61%). The company states it is too early to quantify the longer-term impact.
- Legal Matters: Aggregate provision for legal and other disputes was £0.8 billion as of 30 September 2013. Ultimate liability may vary.
- Currency: Strengthening Sterling against the Yen and exchange losses on intercompany transactions negatively impacted reported results.
Investor Verification Checklist
- China Exposure: Verify the duration and potential financial impact of the ongoing government investigation in China, which caused a 61% sales drop in the region.
- Divestiture Completion: Confirm the closing dates and final proceeds for the Lucozade/Ribena and Arixtra/Fraxiparine sales to ensure the £2 billion+ value is realized.
- US De-stocking: Monitor US wholesaler inventory levels to determine if the reported 3 percentage point drag on growth is temporary or indicative of broader market trends.
- Pipeline Milestones: Track the regulatory decisions for Anoro Ellipta (COPD) and the Phase III data read-outs for assets like drisapersen and vercirnon, which previously reported negative data.
- Core vs. Total EPS: Analyze the widening gap between Core EPS (+16%) and Total EPS (-12%) to understand the magnitude of non-core charges (restructuring, legal, amortization) impacting statutory earnings.